• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
GLP-1 discontinuation and reinitiation trends study published in JAMA Network Open

GLP-1 discontinuation and reinitiation trends study published in JAMA Network Open

by Truveta staff | Jan 31, 2025 | Research

Discontinuation within one year was significantly higher in patients without T2D (64.8%) compared to those with T2D (46.5%). When patients experienced greater weight loss, they were less likely to discontinue the GLP-1 RA medications. Among patients with T2D, higher...
GLP-1 RA prescription trends: January 2018 – September 2024

GLP-1 RA prescription trends: January 2018 – September 2024

by Truveta staff | Oct 14, 2024 | Research

Overall prescribing rates for GLP-1 medications increased in September 2024 relative to June 2024 (+11.9%). While the rate of GLP-1 prescriptions labeled for type 2 diabetes were about the same as June 2024 (+4.0%), the rate of prescriptions for GLP-1 medications...
ISPE 2024: Real-world patterns in GLP-1 RA switching from 2018-2023 in the US

ISPE 2024: Real-world patterns in GLP-1 RA switching from 2018-2023 in the US

by Truveta Research | Aug 22, 2024 | Research, Research Insights

Authors: Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD MPH ⊕Truveta, Inc, Bellevue, WA, Samuel Gratzl, PhD ⊕Truveta, Inc, Bellevue, WA, Charlotte Baker, DrPH MPH CPH ⊕Truveta, Inc, Bellevue, WA, Duy Do, PhD ⊕Truveta, Inc,...

Share this


Recent posts

  • Truveta leads a new era in cancer research with the most complete, representative, and timely real-world data on all cancers
  • Top 5 takeaways from Truveta Symposium 2025
  • Women’s health: Pain medication remains rare for women receiving IUDs

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Get started

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Interested in learning more?

Our website uses cookies to ensure you have the best experience.AcceptPrivacy notice